File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3390/biomedicines10061444
- Scopus: eid_2-s2.0-85132702417
- WOS: WOS:000816565900001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: The Emerging Role of Branched-Chain Amino Acids in Liver Diseases
Title | The Emerging Role of Branched-Chain Amino Acids in Liver Diseases |
---|---|
Authors | |
Keywords | branched-chain amino acids cirrhosis hepatocellular carcinoma liver diseases non-alcoholic fatty liver disease |
Issue Date | 18-Jun-2022 |
Publisher | MDPI |
Citation | Biomedicines, 2022, v. 10, n. 6 How to Cite? |
Abstract | Chronic liver diseases pose a substantial health burden worldwide, with approximately two million deaths each year. Branched-chain amino acids (BCAAs)—valine, leucine, and isoleucine—are a group of essential amino acids that are essential for human health. Despite the necessity of a dietary intake of BCAA, emerging data indicate the undeniable correlation between elevated circulating BCAA levels and chronic liver diseases, including non-alcoholic fatty liver diseases (NAFLD), cirrho-sis, and hepatocellular carcinoma (HCC). Moreover, circulatory BCAAs were positively associated with a higher cholesterol level, liver fat content, and insulin resistance (IR). However, BCAA supple-mentation was found to provide positive outcomes in cirrhosis and HCC patients. This review will attempt to address the contradictory claims found in the literature, with a special focus on BCAAs’ distribution, key signaling pathways, and the modulation of gut microbiota. This should provide a better understanding of BCAAs’ possible contribution to liver health. |
Persistent Identifier | http://hdl.handle.net/10722/340260 |
ISSN | 2023 Impact Factor: 3.9 2023 SCImago Journal Rankings: 0.962 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lo, EKK | - |
dc.contributor.author | Felicianna | - |
dc.contributor.author | Xu, JH | - |
dc.contributor.author | Zhan, Q | - |
dc.contributor.author | Zeng, Z | - |
dc.contributor.author | El-Nezami, H | - |
dc.date.accessioned | 2024-03-11T10:42:51Z | - |
dc.date.available | 2024-03-11T10:42:51Z | - |
dc.date.issued | 2022-06-18 | - |
dc.identifier.citation | Biomedicines, 2022, v. 10, n. 6 | - |
dc.identifier.issn | 2227-9059 | - |
dc.identifier.uri | http://hdl.handle.net/10722/340260 | - |
dc.description.abstract | Chronic liver diseases pose a substantial health burden worldwide, with approximately two million deaths each year. Branched-chain amino acids (BCAAs)—valine, leucine, and isoleucine—are a group of essential amino acids that are essential for human health. Despite the necessity of a dietary intake of BCAA, emerging data indicate the undeniable correlation between elevated circulating BCAA levels and chronic liver diseases, including non-alcoholic fatty liver diseases (NAFLD), cirrho-sis, and hepatocellular carcinoma (HCC). Moreover, circulatory BCAAs were positively associated with a higher cholesterol level, liver fat content, and insulin resistance (IR). However, BCAA supple-mentation was found to provide positive outcomes in cirrhosis and HCC patients. This review will attempt to address the contradictory claims found in the literature, with a special focus on BCAAs’ distribution, key signaling pathways, and the modulation of gut microbiota. This should provide a better understanding of BCAAs’ possible contribution to liver health. | - |
dc.language | eng | - |
dc.publisher | MDPI | - |
dc.relation.ispartof | Biomedicines | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | branched-chain amino acids | - |
dc.subject | cirrhosis | - |
dc.subject | hepatocellular carcinoma | - |
dc.subject | liver diseases | - |
dc.subject | non-alcoholic fatty liver disease | - |
dc.title | The Emerging Role of Branched-Chain Amino Acids in Liver Diseases | - |
dc.type | Article | - |
dc.identifier.doi | 10.3390/biomedicines10061444 | - |
dc.identifier.scopus | eid_2-s2.0-85132702417 | - |
dc.identifier.volume | 10 | - |
dc.identifier.issue | 6 | - |
dc.identifier.eissn | 2227-9059 | - |
dc.identifier.isi | WOS:000816565900001 | - |
dc.identifier.issnl | 2227-9059 | - |